Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Significant Growth in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 517,820 shares, a growth of 169.5% from the July 15th total of 192,173 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily volume of 7,426,518 shares, the short-interest ratio is currently 0.1 days.

Kairos Pharma Stock Performance

NYSEAMERICAN:KAPA opened at $0.36 on Friday. The business has a 50 day moving average price of $0.37 and a 200-day moving average price of $0.51. The firm has a market cap of $7.71 million, a PE ratio of -1.29 and a beta of 1.56. Kairos Pharma has a fifty-two week low of $0.27 and a fifty-two week high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter. Research analysts predict that Kairos Pharma will post -0.37 EPS for the current year.

Institutional Trading of Kairos Pharma

A hedge fund recently raised its stake in Kairos Pharma stock. XTX Topco Ltd raised its holdings in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) by 290.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,494 shares of the company’s stock after purchasing an additional 36,086 shares during the period. XTX Topco Ltd owned approximately 0.23% of Kairos Pharma worth $34,000 at the end of the most recent quarter.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.